The Medicines Company has terminated its Phase 2b dose-ranging study of MDCO-2010, a serine protease inhibitor due to the serious unexpected patient safety issues encountered during the trial. The MDCO-2010 was being developed as an intravenous antifibrinolytic drug for the reduction of blood loss during surgery. Although the cause of the safety issues and any potential link to the study drug are still under analysis, the company had determined not only to end the trial but also stop further development of MDCO-2010 due to evidence of risk to patients.
